



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PCSK9-IN-10

Cat. No.:	HY-152221
CAS No.:	368434-98-4
Molecular Formula:	C ₁₈ H ₂₃ N ₅ O ₄
Molecular Weight:	373.41
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (669.51 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.6780 mL	13.3901 mL	26.7802 mL
		5 mM		0.5356 mL	2.6780 mL	5.3560 mL
		10 mM		0.2678 mL	1.3390 mL	2.6780 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.57 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.57 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 2.08 mg/mL (5.57 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC ₅₀ value of 6.4 μM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia ^[1] .
In Vitro	PCSK9-IN-10 (compound 3s) (0, 2.5, 5, 12.5, 25 μM; 24 h) significantly decreases the PCSK9 protein expression and increases the expression of LDL receptor (LDLR) in a dose dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay ^[1]

	Cell Line:	HepG2 cells
	Concentration:	0-1000 μ M
	Incubation Time:	24 h
	Result:	Showed low cytotoxicity to HepG2 cells.
	Western Blot Analysis ^[1]	
	Cell Line:	HepG2 cells
	Concentration:	0, 2.5, 5, 12.5, 25 μ M
	Incubation Time:	24 h
In Vivo	Result:	Significantly decreased PCSK9 protein level in a dose dependent manner.
	PCSK9-IN-10 (30 mg/kg; p.o.; once a day for 8 weeks) reduces total cholesterol (TC) and atherosclerotic plaque size in ApoE KO mice ^[1] .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Eight weeks old male ApoE KO mice ^[1]
	Dosage:	30 mg/kg
	Administration:	P.o.; once a day for 8 weeks
	Result:	Inhibited both hepatic and serum PCSK9 content obviously and reduced reduced atherosclerotic plaque size.

REFERENCES

[1]. Qiao MQ, et al. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis. Eur J Med Chem. 2022 Dec 26;247:115047.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA